Insulet Corporation (PODD)

US — Healthcare Sector
Peers: TNDM  DXCM  INSP  PEN  MASI 

Automate Your Wheel Strategy on PODD

With Tiblio's Option Bot, you can configure your own wheel strategy including PODD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PODD
  • Rev/Share 33.549
  • Book/Share 20.8019
  • PB 15.7616
  • Debt/Equity 0.9568
  • CurrentRatio 2.2569
  • ROIC 0.1217

 

  • MktCap 23078181125.0
  • FreeCF/Share 5.5823
  • PFCF 58.7829
  • PE 97.6607
  • Debt/Assets 0.4035
  • DivYield 0
  • ROE 0.1843

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation PODD Truist -- Buy -- $365 June 16, 2025
Initiation PODD Goldman -- Buy -- $380 May 30, 2025
Upgrade PODD Wolfe Research Peer Perform Outperform -- $350 May 13, 2025
Downgrade PODD Wolfe Research Outperform Peer Perform -- -- April 29, 2025
Initiation PODD RBC Capital Mkts -- Outperform -- $340 March 6, 2025

News

Final Trades: Rocket Companies, Cisco Systems, Insulet Corp and the IGV
CSCO, PODD, RKT
Published: August 19, 2025 by: CNBC Television
Sentiment: Neutral

The Investment Committee give you their top stocks to watch for the second half.

Read More
image for news Final Trades: Rocket Companies, Cisco Systems, Insulet Corp and the IGV
Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise
PODD
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Positive

PODD posts strong Q2 earnings and revenues and lifts its 2025 outlook, marking a decade of 20%+ constant-currency growth.

Read More
image for news Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
PODD
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Insulet Corporation (PODD) Q2 2025 Earnings Call Transcript
PODD
Published: August 07, 2025 by: Seeking Alpha
Sentiment: Neutral

Insulet Corporation (NASDAQ:PODD ) Q2 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Ana Maria Chadwick - Executive VP & CFO Ashley A. McEvoy - CEO, President & Director Eric Benjamin - Executive VP, Chief Product & Customer Experience Officer June Lazaroff - Senior Director of Investor Relations Conference Call Participants Danielle Joy Antalffy - UBS Investment Bank, Research Division David Harrison Roman - Goldman Sachs Group, Inc., Research Division Issie Kirby - Redburn (Europe) Limited, Research Division Jayson Tyler Bedford - Raymond James & Associates, Inc., Research Division Jeffrey D.

Read More
image for news Insulet Corporation (PODD) Q2 2025 Earnings Call Transcript
Insulet (PODD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
PODD
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Neutral

While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Read More
image for news Insulet (PODD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Insulet (PODD) Surpasses Q2 Earnings and Revenue Estimates
PODD
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive

Insulet (PODD) came out with quarterly earnings of $1.17 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.55 per share a year ago.

Read More
image for news Insulet (PODD) Surpasses Q2 Earnings and Revenue Estimates
Curious about Insulet (PODD) Q2 Performance? Explore Wall Street Estimates for Key Metrics
PODD
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.

Read More
image for news Curious about Insulet (PODD) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
ABBV, PODD
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Read More
image for news Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth
PODD
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive

Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth
Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report?
PODD
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive

Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Read More
image for news Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report?
Here's Why You Should Retain PODD Stock in Your Portfolio Now
PODD
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive

Insulet's Omnipod 5 gains traction with global expansion and rising Type 2 adoption despite economic and competitive hurdles.

Read More
image for news Here's Why You Should Retain PODD Stock in Your Portfolio Now
Here's Why Insulet (PODD) is a Strong Growth Stock
PODD
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Here's Why Insulet (PODD) is a Strong Growth Stock
S&P 500 Wraps Up Best May Since 1990: 5 Top Stocks in the ETF
CEG, MCHP, NRG, PODD, STX
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive

SPY jumped 6.3% in May, the most in decades, led by standout gains in NRG, STX, CEG, PODD and MCHP amid easing trade fears.

Read More
image for news S&P 500 Wraps Up Best May Since 1990: 5 Top Stocks in the ETF
Insulet Gains 78.5% in a Year: What's Driving the Stock?
PODD
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive

PODD's shares rise on the back of Omnipod 5's growth, global expansion, and strong Q1 2025 gains despite rising operating costs and macro headwinds.

Read More
image for news Insulet Gains 78.5% in a Year: What's Driving the Stock?
Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
PODD
Published: May 23, 2025 by: Business Wire
Sentiment: Neutral

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami on Tuesday, June 10, 2025 at 9:20 a.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit investors.insulet.com/events. A replay of the webcast will also be available followin.

Read More
image for news Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
4 Medical Product Stocks to Watch From a Challenging Industry
ALUR, CLRB, MGNX, PODD
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Negative

The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals.

Read More
image for news 4 Medical Product Stocks to Watch From a Challenging Industry
Here's Why Insulet (PODD) is a Strong Momentum Stock
PODD
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Here's Why Insulet (PODD) is a Strong Momentum Stock
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
PODD
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Insulet Q1 Earnings Top Estimates, Stock Up, 2025 Sales View Raised
PODD
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive

PODD delivers better-than-expected earnings and revenues in the first quarter of 2025.

Read More
image for news Insulet Q1 Earnings Top Estimates, Stock Up, 2025 Sales View Raised
Top Stock Movers Now: Tesla, Monster Beverage, Insulet, and More
MNST, PODD, TSLA
Published: May 09, 2025 by: Investopedia
Sentiment: Neutral

U.S. equities were mixed and little changed at midday as the markets awaited key trade talks between the U.S. and China set for this weekend. The Dow Jones Industrial Average edged lower, while the S&P 500 and Nasdaq were slightly higher.

Read More
image for news Top Stock Movers Now: Tesla, Monster Beverage, Insulet, and More
Insulet Is the Top S&P 500 Performer Today. Here's Why.
PODD
Published: May 09, 2025 by: Barrons
Sentiment: Positive

The insulin pump maker beat earnings expectations for the first quarter and raised its forecast for 2025.

Read More
image for news Insulet Is the Top S&P 500 Performer Today. Here's Why.
Insulet Corporation (PODD) Q1 2025 Earnings Call Transcript
PODD
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral

Insulet Corporation (NASDAQ:PODD ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants June Lazaroff - Senior Director, IR Tim Scannell - Chair Ashley McEvoy - President and CEO Ana Chadwick - EVP and CFO Eric Benjamin - Chief Product and Customer Experience Officer Conference Call Participants Travis Steve - Bank of America Robbie Marcus - JPMorgan Jeff Johnson - Baird Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Patrick Wood - Morgan Stanley Marie Thibault - BTIG Michael Polark - Wolfe Research Matt O'Brien - Piper Sandler Steve Lichtman - Oppenheimer Issie Kirby - …

Read More
image for news Insulet Corporation (PODD) Q1 2025 Earnings Call Transcript
Curious about Insulet (PODD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
PODD
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.

Read More
image for news Curious about Insulet (PODD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
4 Medical Product Stocks to Buy From a Challenging Industry
ALUR, CLRB, MGNX, PODD
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive

The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors.

Read More
image for news 4 Medical Product Stocks to Buy From a Challenging Industry
PODD Stock Benefits From the Launch of Omnipod 5 in Canada
PODD
Published: April 08, 2025 by: Zacks Investment Research
Sentiment: Positive

Insulet announces the commercial launch of Omnipod 5 AID system in Canada, with Dexcom G6 and G7 CGM sensor compatibility.

Read More
image for news PODD Stock Benefits From the Launch of Omnipod 5 in Canada
PODD Stock Gains Following the Launch of Omnipod 5 in Australia
PODD
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive

Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.

Read More
image for news PODD Stock Gains Following the Launch of Omnipod 5 in Australia
PODD Stock to Gain From Favorable RADIANT Trial Results for Omnipod 5
PODD
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Positive

Insulet unveils positive RADIANT trial clinical data for its Omnipod 5 at the 18th international conference on ATTD.

Read More
image for news PODD Stock to Gain From Favorable RADIANT Trial Results for Omnipod 5
Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst
PODD
Published: February 21, 2025 by: Benzinga
Sentiment: Positive

On Thursday, Insulet Corporation PODD reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the consensus of $1.02.

Read More
image for news Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst
Insulet Corporation (PODD) Q4 2024 Earnings Call Transcript
PODD
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Neutral

Insulet Corporation (NASDAQ:PODD ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants June Lazaroff - Senior Director of Investor Relations Jim Hollingshead - President & Chief Executive Officer Ana Chadwick - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants Robert Marcus - JPMorgan Jeffrey Johnson - Baird Travis Steed - Bank of America Michael Polark - Wolfe Research Issie Kirby - Redburn Atlantic Patrick Wood - Morgan Stanley Macauley Kilbane - William Blair Larry Biegelsen - Wells Fargo Marie Thibault - BTIG Mike Kratky - Leerink Partners Jayson Bedford - Raymond James …

Read More
image for news Insulet Corporation (PODD) Q4 2024 Earnings Call Transcript

About Insulet Corporation (PODD)

  • IPO Date 2007-05-15
  • Website https://www.insulet.com
  • Industry Medical - Devices
  • CEO Ashley A. McEvoy
  • Employees 3900

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.